ONE-TWENTY TWO: Trading Financial Markets
Exploring the poetry in financial markets for students of money and economy since the year 2000.
AT40 = 55.4% of stocks are trading above their respective 40-day moving averages (DMAs) AT200 = 56.7% of stocks are trading above their respective 200DMAs VIX = 12.6 Short-term Trading Call: neutral Commentary The recovery from the February swoon has been full of nearly predictable bounces: whether it was oversold trading conditions or support at … Read more
AT40 = 48.1% of stocks are trading above their respective 40-day moving averages (DMAs) AT200 = 54.9% of stocks are trading above their respective 200DMAs VIX = 11.3 Short-term Trading Call: cautiously bullish Commentary It was by the slimmest of margins, but the S&P 500 (SPY) finally ended a week with a loss. After 8 … Read more
AT40 = 73.8% of stocks are trading above their respective 40-day moving averages (DMAs) – overbought day #7 AT200 = 59.7% of stocks are trading above their respective 200DMAs VIX = 9.7 Short-term Trading Call: bullish Commentary This is what a lift-off for an extended overbought rally looks like. The S&P 500 (SPY) followed its … Read more
AT40 = 71.3% of stocks are trading above their respective 40-day moving averages (DMAs) – overbought day #2 AT200 = 58.6% of stocks are trading above their respective 200DMAs VIX = 9.5 Short-term Trading Call: bullish Commentary It looks like an overbought rally is truly underway. AT40 (T2108), the percentage of stocks closing above their … Read more
AT40 = 53.0% of stocks are trading above their respective 40-day moving averages (DMAs) AT200 = 51.1% of stocks are trading above their respective 200DMAs VIX = 10.7 (down 11.5%) Short-term Trading Call: neutral (see below for caveats) Commentary I had no idea that the previous tensions in the stock market fully priced in the … Read more
Teva Pharmaceuticals (TEVA) lost 24% last Thursday after reporting disappointing earnings. From the Seeking Alpha transcript of the conference call: “All of us at Teva understand the frustration and disappointment our shareholders are feeling… In our U.S. Generics business, we experienced accelerated price erosion and decreased volume, mainly due to customer consolidation, greater competition as … Read more
(This is an excerpt from an article I originally published on Seeking Alpha on August 29, 2016. Click here to read the entire piece.) This is the message actress Sarah Jessica Parker posted on Instagram Thursday, August 25, 2016 to join a chorus of protest and complaint about the extremely high cost of the EpiPen® … Read more